2013 News | Events | Industry Updates
Selcia Limited, the international life sciences CRO, has announced a successful inspection of its GMP radiochemistry facility by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
Selcia Limited, the international life sciences CRO, has appointed John Davis to the newly created role of Director of Discovery.
Selcia Limited, the international life sciences CRO, has entered into a drug discovery collaboration with Cantab Anti-Infectives, the goal of which is to accelerate Cantab’s programme to develop improved antibiotics for multidrug resistant Gram-negative bacterial infections based on the polymyxin nucleus.
Selcia has developed new technology to enable drug discovery and development on the target family of peptidyl-prolyl cis-trans isomerases (PPIases).
Read the article in Genetic Engineering and Biotechnology News GEN (15 Feb 2013, Vol. 44 No. 4) on Targeting Protein-Protein Interactions for an overview of some interesting contributions to the field including Selcia's Affinity Capillary Electrophoresis technology.